Conclusions : C and esartan is superior to losartan in reducing blood pressure .
C and esartan also causes fewer serious adverse events than losartan
Background : C and esartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker ( ARB ) .
Several clinical trials have compared c and esartan with losartan in the management of essential hypertension .
However , systematic assessment of efficacy and safety between c and esartan and losartan is still lacking .
A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II
An 8-week , multicentre ( 72 sites in the US ) , double-blind , r and omised , parallel group , forced titration study compared the antihypertensive efficacy of c and esartan cilexetil and losartan .  A total of 611 patients with essential hypertension ( diastolic blood pressure 95 to 114 mm Hg ) were r and omised initially to c and esartan cilexetil 16 mg once daily or losartan 50 mg once daily . After 2 weeks of r and omised treatment , the doses of c and esartan cilexetil and losartan were doubled to 32 mg and 100 mg once daily and continued respectively for 6 weeks . At week 8 , c and esartan cilexetil lowered the blood pressure ( BP ) at 24 h ( trough ) , 6 h ( peak ) and 48 h post dose to a significantly greater extent ( P < 0.05 ) than losartan : c and esartan cilexetil lowered trough BP by 13.4/10.5 mm Hg , peak BP by 15.5/12.9 mm Hg and 48-h BP by 10.5/9.9 mm Hg compared to a reduction of trough BP by 10.1/9.1 mm Hg , peak BP by 12.0/9.5 mm Hg , and 48-h BP by 5.9/7.0 mm Hg by losartan . The responder and control rates were numerically higher in the c and esartan cilexetil group , but the differences did not reach statistical significance ; the responder rates were 58.8 % for the c and esartan cilexetil group and 52.1 % for the losartan group and control rates were 49.0 % for the c and esartan cilexetil group and 44.6 % for the losartan group . Overall , both treatment regimens were well tolerated . A total of 15 of the 611 ( 2.5 % ) patients withdrew from the study due to an adverse event , including nine ( 2.9 % ) in the c and esartan cilexetil group and six ( 2.0 % ) in the losartan group . In conclusion , this forced titration study confirms that c and esartan cilexetil is more effective in lowering BP than losartan when compared at once daily maximum doses
Conclusions : C and esartan is superior to losartan in reducing blood pressure .
C and esartan also causes fewer serious adverse events than losartan
Background : C and esartan is a relatively novel antihypertensive agent of the angiotensin receptor blocker ( ARB ) .
Several clinical trials have compared c and esartan with losartan in the management of essential hypertension .
However , systematic assessment of efficacy and safety between c and esartan and losartan is still lacking .